Patent · US Active

Irreversible covalent inhibitors of the GTPase K-Ras G12C

US9745319B2 · kind B2 · utility

44Cited by

17References

11Claims

0Family size

Assignee

Araxes Pharma LLC · US

Inventors

Pingda Ren · San Diego, US
Yi Liu · San Diego, US
Liansheng Li · San Diego, US
Jun Feng · San Diego, US

Key dates

Filing date	Mar 14, 2014
Grant date	Aug 29, 2017
Priority date	—
Expiry date	Mar 14, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C311/18
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.